Skip to main content
Journal cover image

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.

Publication ,  Journal Article
Long, MD; Herfarth, HH; Pipkin, CA; Porter, CQ; Sandler, RS; Kappelman, MD
Published in: Clin Gastroenterol Hepatol
March 2010

BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) might be at increased risk for certain malignancies. We evaluated the risk of non-melanoma skin cancer (NMSC) in patients with IBD and determined how immunosuppressive and biologic medications affect this risk. METHODS: We performed retrospective cohort and nested case-control studies by using administrative data from PharMetrics Patient Centric Database. In the cohort study, 26,403 patients with Crohn's disease (CD) and 26,974 patients with ulcerative colitis (UC) were each matched to 3 non-IBD controls. NMSC risk was evaluated by incidence rate ratio (IRR). In the nested case-control study, 387 CD patients and 355 UC patients with NMSC were each matched to 4 IBD patients without NMSC by using incidence density sampling. Conditional logistic regression was used to determine the association between specific IBD medication use and NMSC. RESULTS: In the cohort study, the incidence of NMSC was higher among patients with IBD compared with controls (IRR, 1.64; 95% confidence interval [CI], 1.51-1.78). In the nested-case control study, recent thiopurine use (< or =90 days) was associated with NMSC (adjusted odds ratio [OR], 3.56; 95% CI, 2.81-4.50), as was recent biologic use among patients with CD (adjusted OR, 2.07; 95% CI, 1.28-3.33). Persistent thiopurine use (>365 days) was associated with NMSC (adjusted OR, 4.27; 95% CI, 3.08-5.92), as was persistent biologic use among patients with CD (adjusted OR, 2.18; 95% CI, 1.07-4.46). CONCLUSIONS: Patients with IBD, especially those who receive thiopurines, are at risk for NMSC. Appropriate counseling and monitoring of such patients with IBD are recommended.

Duke Scholars

Published In

Clin Gastroenterol Hepatol

DOI

EISSN

1542-7714

Publication Date

March 2010

Volume

8

Issue

3

Start / End Page

268 / 274

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Risk Assessment
  • Retrospective Studies
  • Middle Aged
  • Male
  • Inflammatory Bowel Diseases
  • Incidence
  • Immunosuppressive Agents
  • Humans
  • Gastroenterology & Hepatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Long, M. D., Herfarth, H. H., Pipkin, C. A., Porter, C. Q., Sandler, R. S., & Kappelman, M. D. (2010). Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 8(3), 268–274. https://doi.org/10.1016/j.cgh.2009.11.024
Long, Millie D., Hans H. Herfarth, Clare A. Pipkin, Carol Q. Porter, Robert S. Sandler, and Michael D. Kappelman. “Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.Clin Gastroenterol Hepatol 8, no. 3 (March 2010): 268–74. https://doi.org/10.1016/j.cgh.2009.11.024.
Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010 Mar;8(3):268–74.
Long, Millie D., et al. “Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.Clin Gastroenterol Hepatol, vol. 8, no. 3, Mar. 2010, pp. 268–74. Pubmed, doi:10.1016/j.cgh.2009.11.024.
Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010 Mar;8(3):268–274.
Journal cover image

Published In

Clin Gastroenterol Hepatol

DOI

EISSN

1542-7714

Publication Date

March 2010

Volume

8

Issue

3

Start / End Page

268 / 274

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Risk Assessment
  • Retrospective Studies
  • Middle Aged
  • Male
  • Inflammatory Bowel Diseases
  • Incidence
  • Immunosuppressive Agents
  • Humans
  • Gastroenterology & Hepatology